Your new post is loading...
Researchers discover proteins in the IL-6 signaling pathway may be leveraged as novel biomarkers of multiple sclerosis (MS) to gauge disease activity and as a target for new therapies.
Via Brian Shields
|
Rescooped by Ray and Terry's from Biomarkers and Personalized Medicine |
No comment yet.
Sign up to comment
